Scarica l'app Stockscreener
37.35
5.06%
-1.99
Dopo l'orario di chiusura:
37.00
-0.35
-0.94%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TGTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$39.34
Aprire:
$37.94
Volume 24 ore:
3.13M
Relative Volume:
1.24
Capitalizzazione di mercato:
$4.54B
Reddito:
$264.79M
Utile/perdita netta:
$-14.36M
Rapporto P/E:
-339.55
EPS:
-0.11
Flusso di cassa netto:
$-28.11M
1 W Prestazione:
-6.30%
1M Prestazione:
+4.86%
6M Prestazione:
+68.02%
1 anno Prestazione:
+158.30%
Intervallo 1D:
$36.55
$38.83
Intervallo di 1 settimana:
$36.41
$42.04
Portata 52W:
$12.93
$43.32
Tg Therapeutics Inc Stock (TGTX) Company Profile
Nome
Tg Therapeutics Inc
Settore
Industria
Telefono
(212) 554-4484
Indirizzo
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Confronta TGTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
37.35 | 4.54B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-29 | Iniziato | TD Cowen | Buy |
| 2023-08-02 | Aggiornamento | Goldman | Sell → Neutral |
| 2023-06-26 | Ripresa | Jefferies | Buy |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-01 | Iniziato | JP Morgan | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Iniziato | Evercore ISI | Outperform |
| 2020-01-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2018-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Ripresa | H.C. Wainwright | Buy |
| 2017-04-25 | Iniziato | Jefferies | Buy |
| 2017-03-06 | Reiterato | FBR & Co. | Outperform |
| 2016-10-06 | Ripresa | Brean Capital | Buy |
| 2016-05-27 | Iniziato | SunTrust | Buy |
| 2015-12-01 | Iniziato | FBR Capital | Outperform |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-19 | Reiterato | Brean Capital | Buy |
| 2014-12-11 | Reiterato | ROTH Capital | Buy |
| 2014-12-10 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX) - The Globe and Mail
(TGTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
TGTX Gains as Roche's Ocrevus Fails in Phase 3 Trial; Impacting MS Market Dynamics - GuruFocus
TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug - MSN
TG Therapeutics stock rises as Roche’s trial fails (TGTX) - Seeking Alpha
CRUCIAL INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm - ACCESS Newswire
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%? - Yahoo Finance
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - MSN
Why TG Therapeutics Stock Was Soaring This Week - MSN
Based On Its ROE, Is TG Therapeutics, Inc. (NASDAQ:TGTX) A High Quality Stock? - simplywall.st
(TGTX) Investment Analysis and Advice - Stock Traders Daily
TG Therapeutics stock soars to 52-week high of $43.03 By Investing.com - Investing.com South Africa
TG Therapeutics stock soars to 52-week high of $43.03 - Investing.com India
TG Therapeutics (TGTX) technical analysisTG Therapeutics (NASDAQ:TGTX) - Benzinga
TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts - Yahoo Finance
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, Prevalence, Therapies and Companies by DelveInsight - The Globe and Mail
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 By Investing.com - Investing.com Australia
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics stock soars to 52-week high of $40.32 - Investing.com India
TG Therapeutics Stock (TGTX): Advancing MS Treatment - Value The Markets
Is TG Therapeutics, Inc. (TGTX) the Best Performing Growth Stock in 2025? - Insider Monkey
(TGTX) Technical Data - Stock Traders Daily
TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter (NASDAQ:TGTX) - Seeking Alpha
10 Best Performing Growth Stocks in 2025 - Insider Monkey
Proficio Capital Partners LLC Buys Shares of 10,174 TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics call volume above normal and directionally bullish - TipRanks
Smartleaf Asset Management LLC Has $60,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics (NasdaqCM:TGTX) Surges 28% Following US$23 Million Net Income Turnaround - Yahoo Finance
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? - Benzinga
Bank of New York Mellon Corp Increases Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Q2 Earnings Forecast for TG Therapeutics Issued By B. Riley - Defense World
TGTX Surges on Strong Q4 Results and Briumvi Success - GuruFocus.com
Why TG Therapeutics Shares Are Soaring Now - TipRanks
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week - MSN
TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - Yahoo Finance
Q1 Earnings Forecast for TG Therapeutics Issued By B. Riley - Defense World
This Biotech Stock Hits Buy Point After Earnings Burst - MSN
HC Wainwright Reaffirms “Buy” Rating for TG Therapeutics (NASDAQ:TGTX) - Defense World
TG Therapeutics FY2025 EPS Estimate Boosted by HC Wainwright - Defense World
Why TG Therapeutics, Inc. (TGTX) Surged On Monday? - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Holdings Decreased by Private Advisor Group LLC - Defense World
TG Therapeutics (NASDAQ:TGTX) Upgraded by StockNews.com to Hold Rating - Defense World
TG Therapeutics (NASDAQ:TGTX) Shares Up 5.2% After Earnings Beat - Defense World
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2024 Earnings Call Transcript - MSN
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX) - Defense World
TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide - MSN
Tg Therapeutics Inc Azioni (TGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):